HR and breast cancer: In the preoperative biopsy, breast cancer subtypes were represented in descending order as follows: 190 (46.8%) HR+/HER2−/nd, 118 (29.1%) HR−/HER2−/nd, 58 (14.3%) HR+/HER2+ and 40 (9.9%) HR−/HER2+ disease.